Company / Free Cash Flow
FATE THERAPEUTICS INC Free Cash Flow History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$123.6M
FY2025
5-year range
-$283.8M / -$44.2M
FY2021-FY2025
Trend
+10.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Free Cash Flow has fluctuated over the past 10 years, ranging from -$284M in FY2023 to -$20M in FY2017.
Based on SEC 10-K filings.
-$124M in FY2025.
Improved from -$284M to -$124M over the past 2 years.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, free cash flow increased 10.7% year-over-year.
- Peak free cash flow was recorded in FY2017.
- Lowest free cash flow in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 632.81 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$123.6M | +10.7% |
| FY2024 | -$138.4M | +51.2% |
| FY2023 | -$283.8M | -542.6% |
| FY2022 | -$44.2M | +51.2% |
| FY2021 | -$90.6M | -121.2% |
| FY2020 | -$41.0M | -6.3% |
| FY2019 | -$38.5M | -27.3% |
| FY2018 | -$30.3M | -52.2% |
| FY2017 | -$19.9M | +14.6% |
| FY2016 | -$23.3M | -49.2% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026